FDA Approves Relacorilant with Nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Why It Matters

The new regimen offers a clinically meaningful survival advantage in a setting with limited options, potentially reshaping treatment standards for platinum‑resistant ovarian cancers.

Key Takeaways

• FDA greenlights relacorilant + nab‑paclitaxel for platinum‑resistant ovarian cancer
• Trial shows 1‑month PFS improvement, hazard ratio 0.70
• Overall survival extended by 4.1 months, hazard ratio 0.65
• Oral relacorilant taken three days per nab‑paclitaxel cycle
• Contraindicated for patients requiring chronic corticosteroid therapy

Pulse Analysis

Platinum‑resistant ovarian, fallopian tube and primary peritoneal cancers have long challenged oncologists, as standard chemotherapies lose efficacy after first‑line treatment. The disease’s aggressive biology and limited therapeutic arsenal drive high mortality rates, prompting a search for novel mechanisms of action. Glucocorticoid‑receptor antagonism, the strategy behind relacorilant, aims to disrupt tumor‑promoting stress pathways, offering a fresh angle beyond traditional cytotoxic agents.

The ROSELLA Phase III trial enrolled 381 heavily pre‑treated patients and compared nab‑paclitaxel alone with the same chemotherapy plus relacorilant. The combination extended median progression‑free survival by one month and overall survival by over four months, translating into hazard ratios of 0.70 and 0.65 respectively—statistically robust improvements in a hard‑to‑treat population. Safety signals were manageable, with hematologic toxicities and fatigue most common, while the regimen’s oral component simplifies administration compared with fully intravenous regimens.

For the oncology market, the approval signals a shift toward targeted adjuncts that modulate the tumor microenvironment. Corcept Therapeutics stands to gain a foothold in the lucrative ovarian‑cancer space, and the accelerated FDA review—completed 3.5 months ahead of schedule—highlights regulatory openness to innovative combos. Clinicians may adopt the regimen quickly, especially for patients who have exhausted bevacizumab‑based options, while payers will scrutinize cost‑effectiveness given the modest but meaningful survival gains. Ongoing studies could expand relacorilant’s use to other glucocorticoid‑driven malignancies, further broadening its commercial potential.